EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants (HIDVID Trial): Study Protocol for a Randomized Controlled Study

Dominika Paw iD, Renata Bokiniec, Alicja Kołodziejczyk-Nowotarska iD

Nutrients · 2024

DOI: 10.3390/nu16050700 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Nutrients, 2024. Verfasst von Dominika Paw und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology and Neonatal Intensive Care, Medical University of Warsaw, 00-315 Warsaw, Poland. Hauptthemen laut MEDLINE: Bone Diseases, Metabolic, Vitamin D Deficiency. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitamin D deficiency can escalate prematurity bone disease in preterm infants and negatively influence their immature immunology system. Infants born at 24 + 0/7 weeks to 32 + 6/7 weeks of gestation will be considered for inclusion. Cord or vein blood samples will be obtained within 48 h after birth for 25-hydroxyvitamin D level measurements. Parathyroid hormone and interleukin-6 levels will be measured. Infants will be randomized to the monitored group (i.e., an initial dose of 1000 IU/day and possible modification) or the controlled group (i.e., 250 IU/day or 500 IU/day dose, depending on weight). Supplementation will be monitored up to a postconceptional age of 35 weeks. The primary endpoint is the percentage of infants with deficient or suboptimal 25-hydroxyvitamin D levels at 28 ± 2 days of age. 25-Hydroxyvitamin D levels will be measured at postconceptional age 35 ± 2 weeks. Secondary goals encompass assessing the occurrence of sepsis, osteopenia, hyperparathyroidism, and interleukin-6 concentration. The aim of this study is to evaluate the efficacy of monitored vitamin D supplementation in a group of preterm infants and ascertain if a high initial dosage of monitored vitamin D supplementation can decrease the occurrence of neonatal sepsis and metabolic bone disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Diseases, MetabolicVitamin D DeficiencyHumansInfant, NewbornCalcifediolDietary SupplementsInfant, PrematureInterleukin-6Randomized Controlled Trials as TopicVitamin DVitamins

Stichwörter der Autor:innen

infantinterleukin-6osteopeniaparathyroid hormoneprematuresepsisvitamin D

Substanzen

CalcifediolInterleukin-6Vitamin DVitamins

Autor:innen und Institutionen

  • Department of Neonatology and Neonatal Intensive Care, Medical University of Warsaw, 00-315 Warsaw, Poland.

ORCID-Profile: Dominika Paw, Alicja Kołodziejczyk-Nowotarska

Zitieren

APA

Paw, D., Bokiniec, R., & Kołodziejczyk-Nowotarska, A. (2024). High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants (HIDVID Trial): Study Protocol for a Randomized Controlled Study. Nutrients. https://doi.org/10.3390/nu16050700

Vancouver

Paw D, Bokiniec R, Kołodziejczyk-Nowotarska A. High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants (HIDVID Trial): Study Protocol for a Randomized Controlled Study. Nutrients. 2024. doi:10.3390/nu16050700

BibTeX
@article{Paw2024,
  author = {Paw, Dominika and Bokiniec, Renata and Kołodziejczyk-Nowotarska, Alicja},
  title = {High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants (HIDVID Trial): Study Protocol for a Randomized Controlled Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16050700}
}
Kostenlos starten →